Identification

Name
Aminohippuric acid
Accession Number
DB00345  (APRD00792)
Type
Small Molecule
Groups
Approved
Description

The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

Structure
Thumb
Synonyms
  • 4-aminohippuric acid
  • Aminohippurate
  • N-(p-Aminobenzoyl)aminoacetic acid
  • N-(p-Aminobenzoyl)glycine
  • N-(para-aminobenzoyl)glycine
  • p-aminohippurate
  • p-aminohippuric acid
  • PAH
  • PAHA
  • para-aminohippurate
  • para-aminohippuric acid
  • paraaminohippuric acid
Product Ingredients
IngredientUNIICASInChI Key
Aminohippurate sodiumSUO3KVS1O994-16-6UNZMYCAEMNVPHX-UHFFFAOYSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aminohippurate Sodium Inj Liq 20%Liquid20 %IntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1991-12-311999-11-12Canada
Aminohippurate Sodium PahInjection, solution2 g/10mLIntravenousMerck Sharp & Dohme Limited1944-12-302017-05-10Us
Categories
UNII
Y79XT83BJ9
CAS number
61-78-9
Weight
Average: 194.1873
Monoisotopic: 194.069142196
Chemical Formula
C9H10N2O3
InChI Key
HSMNQINEKMPTIC-UHFFFAOYSA-N
InChI
InChI=1S/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)
IUPAC Name
2-[(4-aminophenyl)formamido]acetic acid
SMILES
NC1=CC=C(C=C1)C(=O)NCC(O)=O

Pharmacology

Indication

Used to measure effective renal plasma flow (ERPF) and to determine the functional capacity of the tubular excretory mechanism.

Structured Indications
Pharmacodynamics

Aminohippurate (p-aminohippuric acid, PAH, PAHA) is the glycine amide of p-aminobenzoic acid. It is filtered by the glomeruli and is actively secreted by the proximal tubules. At low plasma concentrations (1.0 to 2.0 mg/100 mL), an average of 90 percent of aminohippurate is cleared by the kidneys from the renal blood stream in a single circulation. It is ideally suited for measurement of ERPF since it has a high clearance, is essentially nontoxic at the plasma concentrations reached with recommended doses, and its analytical determination is relatively simple and accurate. Aminohippurate is also used to measure the functional capacity of the renal tubular secretory mechanism or transport maximum (TmPAH). This is accomplished by elevating the plasma concentration to levels (40-60 mg/100 mL) sufficient to saturate the maximal capacity of the tubular cells to secrete aminohippurate. Inulin clearance is generally measured during TmPAH determinations since glomerular filtration rate (GFR) must be known before calculations of secretory Tm measurements can be done.

Mechanism of action

Aminohippurate is filtered by the renal glomeruli and secreted into the urine by the proximal tubules. By measuring the amount of drug in the urine it is possible to determine functional capacity and effective renal plasma flow.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

The intravenous LD50 in female mice is 7.22 g/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Aminohippuric acid.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Aminohippuric acid.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Aminohippuric acid.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Aminohippuric acid.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Aminohippuric acid.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Aminohippuric acid.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Aminohippuric acid.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Aminohippuric acid.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Aminohippuric acid.Withdrawn
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Aminohippuric acid.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Aminohippuric acid.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Aminohippuric acid.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Aminohippuric acid.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Aminohippuric acid.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Aminohippuric acid.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Aminohippuric acid.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Aminohippuric acid.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Aminohippuric acid.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Aminohippuric acid.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Aminohippuric acid.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Aminohippuric acid.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Aminohippuric acid.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Aminohippuric acid.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Aminohippuric acid.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Aminohippuric acid.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Aminohippuric acid.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Aminohippuric acid.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Aminohippuric acid.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Aminohippuric acid.Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Aminohippuric acid.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Aminohippuric acid.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Aminohippuric acid.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Aminohippuric acid.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Aminohippuric acid.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Aminohippuric acid.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Aminohippuric acid.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Aminohippuric acid.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Aminohippuric acid.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Aminohippuric acid.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Aminohippuric acid.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Aminohippuric acid.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Aminohippuric acid.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Aminohippuric acid.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Aminohippuric acid.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Aminohippuric acid.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Aminohippuric acid.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Aminohippuric acid.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Aminohippuric acid.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Aminohippuric acid.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Aminohippuric acid.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Aminohippuric acid.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Aminohippuric acid.Approved, Investigational
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Aminohippuric acid.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Aminohippuric acid.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Aminohippuric acid.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Aminohippuric acid.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Aminohippuric acid.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Aminohippuric acid.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Aminohippuric acid.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Aminohippuric acid.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Aminohippuric acid.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Aminohippuric acid.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Aminohippuric acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Aminohippuric acid.Approved
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Aminohippuric acid.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Aminohippuric acid.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Aminohippuric acid.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Aminohippuric acid.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Aminohippuric acid.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Aminohippuric acid.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Aminohippuric acid.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Aminohippuric acid.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Aminohippuric acid.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Aminohippuric acid.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Aminohippuric acid.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Aminohippuric acid.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Aminohippuric acid.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Aminohippuric acid.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Aminohippuric acid.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Aminohippuric acid.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Aminohippuric acid.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Aminohippuric acid.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Aminohippuric acid.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Aminohippuric acid.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Aminohippuric acid.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Aminohippuric acid.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Aminohippuric acid.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Aminohippuric acid.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Aminohippuric acid.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Aminohippuric acid.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Aminohippuric acid.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Aminohippuric acid.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Aminohippuric acid.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Aminohippuric acid.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Aminohippuric acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Aminohippuric acid.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Aminohippuric acid.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Aminohippuric acid.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Aminohippuric acid.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Aminohippuric acid.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Aminohippuric acid.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Aminohippuric acid.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Aminohippuric acid.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Aminohippuric acid.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Aminohippuric acid.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Aminohippuric acid.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Aminohippuric acid.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Aminohippuric acid.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Aminohippuric acid.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Aminohippuric acid.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Aminohippuric acid.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Aminohippuric acid.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Aminohippuric acid.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Aminohippuric acid.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Aminohippuric acid.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Aminohippuric acid.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Aminohippuric acid.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Aminohippuric acid.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Aminohippuric acid.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Aminohippuric acid.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Aminohippuric acid.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Aminohippuric acid.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Aminohippuric acid.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Aminohippuric acid.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Aminohippuric acid.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Aminohippuric acid.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Aminohippuric acid.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Aminohippuric acid.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Aminohippuric acid.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Aminohippuric acid.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Aminohippuric acid.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Aminohippuric acid.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Aminohippuric acid.Experimental
SulpirideThe risk or severity of adverse effects can be increased when Aminohippuric acid is combined with Sulpiride.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Aminohippuric acid.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Aminohippuric acid.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Aminohippuric acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Aminohippuric acid.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Aminohippuric acid.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Aminohippuric acid.Approved
TeriflunomideThe serum concentration of Aminohippuric acid can be increased when it is combined with Teriflunomide.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Aminohippuric acid.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Aminohippuric acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Aminohippuric acid.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Aminohippuric acid.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Aminohippuric acid.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Aminohippuric acid.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Aminohippuric acid.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Aminohippuric acid.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Aminohippuric acid.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Aminohippuric acid.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Aminohippuric acid.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Aminohippuric acid.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Aminohippuric acid.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Aminohippuric acid.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Aminohippuric acid.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Aminohippuric acid.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Aminohippuric acid.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Aminohippuric acid.Approved
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB01867
KEGG Drug
D06890
PubChem Compound
2148
PubChem Substance
46507106
ChemSpider
2063
ChEBI
104011
ChEMBL
CHEMBL463
PharmGKB
PA134711723
RxList
RxList Drug Page
Wikipedia
Aminohippuric_Acid
ATC Codes
V04CH30 — Aminohippuric acid
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (66.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherHypertensive / Insulin Resistance1
1CompletedTreatmentInfections, Human Immunodeficiency Virus and Tuberculosis1
4Unknown StatusTreatmentHealthy Male and Female Volunteers1
Not AvailableActive Not RecruitingOtherDiabetes Mellitus (DM)1
Not AvailableActive Not RecruitingOtherHypertensive1
Not AvailableCompletedTreatmentFatty Acids, Nonesterified / Glomerular Filtration Rate (GFR) / Renal Circulation / Renal Plasma Flow1
Not AvailableWithdrawnOtherHypertensive1

Pharmacoeconomics

Manufacturers
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
LiquidIntravenous20 %
Injection, solutionIntravenous2 g/10mL
Prices
Unit descriptionCostUnit
Aminohippurate 20% vial0.67USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)199-200 °CNot Available
water solubilitySlightly solubleNot Available
logP-2.2Not Available
pKa3.83Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.13 mg/mLALOGPS
logP0ALOGPS
logP-1ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)2.7ChemAxon
pKa (Strongest Basic)4.24ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area92.42 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity50.82 m3·mol-1ChemAxon
Polarizability19.13 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7719
Blood Brain Barrier+0.9304
Caco-2 permeable-0.6601
P-glycoprotein substrateNon-substrate0.7295
P-glycoprotein inhibitor INon-inhibitor0.9782
P-glycoprotein inhibitor IINon-inhibitor0.9841
Renal organic cation transporterNon-inhibitor0.9668
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.8577
CYP450 3A4 substrateNon-substrate0.801
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9381
CYP450 2D6 inhibitorNon-inhibitor0.9552
CYP450 2C19 inhibitorNon-inhibitor0.9338
CYP450 3A4 inhibitorNon-inhibitor0.9055
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9913
Ames testNon AMES toxic0.662
CarcinogenicityNon-carcinogens0.7482
BiodegradationReady biodegradable0.6101
Rat acute toxicity1.5850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9944
hERG inhibition (predictor II)Non-inhibitor0.9731
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0006-0910000000-d6e2bf0631a469ca607b
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00di-3900000000-454a970609f4250f1022
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0006-0910000000-d6e2bf0631a469ca607b
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0f77-2900000000-a8b8a25d88057ce84dd4
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-00di-2900000000-010a61221aacb1a4cd70
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-02fx-9200000000-507831f6ef0e0b10b17a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as hippuric acids. These are compounds containing hippuric acid, which consists of a of a benzoyl group linked to the N-terminal of a glycine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Hippuric acids
Alternative Parents
N-acyl-alpha amino acids / Aminobenzamides / Benzoyl derivatives / Aniline and substituted anilines / Secondary carboxylic acid amides / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Primary amines / Organopnictogen compounds
show 3 more
Substituents
Hippuric acid / N-acyl-alpha-amino acid / N-acyl-alpha amino acid or derivatives / Alpha-amino acid or derivatives / Aminobenzamide / Aminobenzoic acid or derivatives / Benzoyl / Aniline or substituted anilines / Secondary carboxylic acid amide / Amino acid or derivatives
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
N-acylglycine (CHEBI:104011)

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM: Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem. 1997 Jun 27;272(26):16548-54. [PubMed:9195965]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Cihlar T, Ho ES: Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55. [PubMed:10929807]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  3. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, Endou H: Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 2003 Jan;63(1):143-55. [PubMed:12472777]
  4. Pombrio JM, Giangreco A, Li L, Wempe MF, Anders MW, Sweet DH, Pritchard JB, Ballatori N: Mercapturic acids (N-acetylcysteine S-conjugates) as endogenous substrates for the renal organic anion transporter-1. Mol Pharmacol. 2001 Nov;60(5):1091-9. [PubMed:11641438]
  5. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, Endou H: Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999 Jun;289(3):1301-5. [PubMed:10336520]
  6. Islinger F, Gekle M, Wright SH: Interaction of 2,3-dimercapto-1-propane sulfonate with the human organic anion transporter hOAT1. J Pharmacol Exp Ther. 2001 Nov;299(2):741-7. [PubMed:11602689]
  7. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T: Uraemic toxins induce proximal tubular injury via organic anion transporter 1-mediated uptake. Br J Pharmacol. 2002 Jan;135(2):555-63. [PubMed:11815391]
  8. Groves CE, Munoz L, Bahn A, Burckhardt G, Wright SH: Interaction of cysteine conjugates with human and rabbit organic anion transporter 1. J Pharmacol Exp Ther. 2003 Feb;304(2):560-6. [PubMed:12538807]
  9. Aslamkhan A, Han YH, Walden R, Sweet DH, Pritchard JB: Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am J Physiol Renal Physiol. 2003 Oct;285(4):F775-83. Epub 2003 Jul 1. [PubMed:12837685]
  10. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087]
  11. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961]
  12. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999 Sep;56(3):570-80. [PubMed:10462545]
  13. Ho ES, Lin DC, Mendel DB, Cihlar T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 Mar;11(3):383-93. [PubMed:10703662]
  14. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528]
  15. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014]
  16. Sweet DH, Wolff NA, Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem. 1997 Nov 28;272(48):30088-95. [PubMed:9374486]
  17. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988]
  18. Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, Endou H: Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int. 1999 Dec;56(6):2128-36. [PubMed:10594788]
  19. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557]
  20. Li M, Anderson GD, Phillips BR, Kong W, Shen DD, Wang J: Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. Epub 2006 Jan 24. [PubMed:16434549]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  2. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099]
  3. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
  4. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720]
  5. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777]
  6. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557]
  7. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115]
  8. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  9. Bakhiya A, Bahn A, Burckhardt G, Wolff N: Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem. 2003;13(5):249-56. [PubMed:14586168]
  10. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
  11. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem. 2002 Jul 26;277(30):26934-43. Epub 2002 May 13. [PubMed:12011098]
  12. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  2. Leier I, Hummel-Eisenbeiss J, Cui Y, Keppler D: ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42. [PubMed:10760098]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169]
  2. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 an...
Gene Name
SLCO3A1
Uniprot ID
Q9UIG8
Uniprot Name
Solute carrier organic anion transporter family member 3A1
Molecular Weight
76552.135 Da
References
  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Leier I, Hummel-Eisenbeiss J, Cui Y, Keppler D: ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42. [PubMed:10760098]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Symporter activity
Specific Function
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
Gene Name
SLC16A1
Uniprot ID
P53985
Uniprot Name
Monocarboxylate transporter 1
Molecular Weight
53943.685 Da
References
  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PubMed:10579682]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Sun W, Wu RR, van Poelje PD, Erion MD: Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun. 2001 May 4;283(2):417-22. [PubMed:11327718]
  2. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749]
  3. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:35